2023 World Conference on Lung Cancer (Posters)-EP13.01. Study of NLI Use in the First Line of Atezolizumab Plus Chemotherapy

Pdf Summary

This document provides a summary of a study presented at the WCLC 2023 conference. The study focused on the use of the neutrophil-to-lymphocyte index (NLI) as a biomarker in small cell lung cancer (SCLC) patients treated with atezolizumab plus chemotherapy as a first-line treatment. The researchers aimed to analyze the correlation between high versus low NLI levels and survival outcomes.<br /><br />The study included 118 SCLC patients who received the combination of atezolizumab and chemotherapy. The NLI was calculated at baseline and at the beginning of the third cycle of treatment. The patients were divided into high NLI and low NLI subgroups based on these measurements. The researchers collected clinical, analytical, and pathological variables and performed an inferential analysis comparing the subgroups and their relation to survival.<br /><br />The results showed that 46% of patients had a high NLI at baseline, and 53% had a high NLI at the beginning of the third cycle. There were no significant differences in clinical variables between the high and low NLI subgroups. However, significant differences were observed in the level of leukocytes, monocytes, and lymphocytes in the analytical variables.<br /><br />With a median follow-up of 16 months, the study found a median overall survival of 12.5 months and a median progression-free survival of 5 months. However, there were no significant differences in survival outcomes between the high and low NLI subgroups.<br /><br />The study also compared the NLI levels at baseline and at the beginning of the third cycle and found that a greater difference between the two was associated with a tendency towards lower progression-free survival, although this did not reach statistical significance.<br /><br />In conclusion, the study suggests that the use of NLI as a predictor of survival or response to treatment with immunotherapy plus chemotherapy in SCLC is not supported. Further research is needed to validate these findings.

Asset Subtitle

Ruth Alvarez Cabellos

Meta Tag

Speaker Ruth Alvarez Cabellos

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

neutrophil-to-lymphocyte index

biomarker

small cell lung cancer

SCLC

atezolizumab

chemotherapy

first-line treatment

survival outcomes

clinical variables

progression-free survival